Nephros Cash And Short Term Investments vs Total Current Liabilities Analysis

NEPH Stock

USD 2.19 0.01 0.45%

Nephros financial indicator trend analysis is infinitely more than just investigating Nephros recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nephros is a good investment. Please check the relationship between Nephros Cash And Short Term Investments and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

Cash And Short Term Investments vs Total Current Liabilities

Cash And Short Term Investments vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nephros Cash And Short Term Investments account and Total Current Liabilities. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Nephros' Cash And Short Term Investments and Total Current Liabilities is -0.12. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Nephros, assuming nothing else is changed. The correlation between historical values of Nephros' Cash And Short Term Investments and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Nephros are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Cash And Short Term Investments i.e., Nephros' Cash And Short Term Investments and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.12

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Nephros balance sheet. This account contains Nephros investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Nephros fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Total Current Liabilities

Total Current Liabilities is an item on Nephros balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nephros are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Nephros' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nephros current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.The Nephros' current Issuance Of Capital Stock is estimated to increase to about 6 M, while Selling General Administrative is projected to decrease to under 5.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	5.7M	4.7M	8.2M	8.6M
Total Revenue	10.4M	10.0M	14.2M	14.9M

Gross Profit Total Revenue

Nephros fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Preferred Stock Total Equity	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.3	-0.06	-0.24	0.98	-0.12	0.8	0.55	-0.07	0.4	-0.23	0.61	0.58	0.88	0.68	-0.11	-0.92	-0.61	0.89	-0.49	0.98	-0.23	-0.43	0.7	0.54	0.99
Other Current Liab	0.3		0.31	0.28	0.17	0.17	0.35	0.33	0.24	0.64	-0.29	0.43	0.27	0.4	0.51	0.11	-0.2	-0.47	0.57	0.25	0.19	-0.29	-0.17	0.43	0.56	0.21
Total Current Liabilities	-0.06	0.31		0.53	-0.1	0.33	-0.3	-0.2	0.09	0.04	-0.27	-0.07	0.29	-0.11	-0.17	0.45	0.18	0.24	0.1	0.34	-0.12	-0.27	0.14	-0.18	-0.15	-0.1
Accounts Payable	-0.24	0.28	0.53		-0.31	0.03	-0.37	-0.24	0.09	-0.38	-0.29	-0.09	-0.23	-0.38	-0.21	-0.26	0.3	0.52	-0.07	0.32	-0.33	-0.29	0.18	-0.49	-0.2	-0.26
Cash	0.98	0.17	-0.1	-0.31		-0.1	0.74	0.51	-0.06	0.32	-0.18	0.51	0.58	0.84	0.62	-0.11	-0.94	-0.54	0.8	-0.53	0.99	-0.18	-0.37	0.63	0.49	0.99
Other Assets	-0.12	0.17	0.33	0.03	-0.1		-0.47	0.21	0.45	0.1	-0.26	-0.48	0.0	-0.19	-0.29	0.54	0.01	0.16	-0.07	0.66	-0.12	-0.27	0.39	-0.1	-0.3	-0.15
Common Stock Shares Outstanding	0.8	0.35	-0.3	-0.37	0.74	-0.47		0.42	-0.16	0.44	-0.07	0.81	0.48	0.86	0.85	-0.27	-0.68	-0.82	0.74	-0.62	0.78	-0.07	-0.46	0.75	0.79	0.78
Other Current Assets	0.55	0.33	-0.2	-0.24	0.51	0.21	0.42		-0.14	0.33	-0.31	0.32	0.0	0.64	0.43	0.1	-0.67	-0.48	0.53	0.18	0.52	-0.32	-0.25	0.5	0.35	0.53
Total Liab	-0.07	0.24	0.09	0.09	-0.06	0.45	-0.16	-0.14		0.19	0.02	-0.12	0.05	-0.31	-0.11	0.0	0.03	-0.08	0.1	0.4	-0.06	0.02	0.55	0.04	-0.09	-0.12
Preferred Stock Total Equity	0.4	0.64	0.04	-0.38	0.32	0.1	0.44	0.33	0.19		0.19	0.26	0.41	0.51	0.3	0.32	-0.27	-0.76	0.6	0.1	0.3	0.19	-0.35	0.84	0.32	0.29
Common Stock	-0.23	-0.29	-0.27	-0.29	-0.18	-0.26	-0.07	-0.31	0.02	0.19		-0.48	-0.05	-0.14	-0.49	-0.1	0.24	-0.18	-0.23	0.01	-0.19	1.0	-0.16	0.2	-0.44	-0.24
Property Plant Equipment	0.61	0.43	-0.07	-0.09	0.51	-0.48	0.81	0.32	-0.12	0.26	-0.48		0.38	0.65	0.91	-0.2	-0.48	-0.56	0.64	-0.51	0.56	-0.48	-0.31	0.45	0.87	0.59
Short Long Term Debt Total	0.58	0.27	0.29	-0.23	0.58	0.0	0.48	0.0	0.05	0.41	-0.05	0.38		0.56	0.49	0.16	-0.38	-0.47	0.55	-0.33	0.59	-0.06	-0.31	0.47	0.43	0.56
Total Stockholder Equity	0.88	0.4	-0.11	-0.38	0.84	-0.19	0.86	0.64	-0.31	0.51	-0.14	0.65	0.56		0.76	0.06	-0.82	-0.77	0.78	-0.45	0.86	-0.15	-0.62	0.77	0.68	0.87
Property Plant And Equipment Net	0.68	0.51	-0.17	-0.21	0.62	-0.29	0.85	0.43	-0.11	0.3	-0.49	0.91	0.49	0.76		-0.18	-0.6	-0.6	0.64	-0.51	0.67	-0.49	-0.28	0.47	0.98	0.68
Current Deferred Revenue	-0.11	0.11	0.45	-0.26	-0.11	0.54	-0.27	0.1	0.0	0.32	-0.1	-0.2	0.16	0.06	-0.18		0.02	-0.08	-0.11	0.33	-0.11	-0.1	-0.19	0.1	-0.15	-0.13
Net Debt	-0.92	-0.2	0.18	0.3	-0.94	0.01	-0.68	-0.67	0.03	-0.27	0.24	-0.48	-0.38	-0.82	-0.6	0.02		0.52	-0.72	0.4	-0.95	0.24	0.4	-0.58	-0.48	-0.94
Retained Earnings	-0.61	-0.47	0.24	0.52	-0.54	0.16	-0.82	-0.48	-0.08	-0.76	-0.18	-0.56	-0.47	-0.77	-0.6	-0.08	0.52		-0.69	0.2	-0.57	-0.17	0.46	-0.93	-0.57	-0.55
Non Current Assets Total	0.89	0.57	0.1	-0.07	0.8	-0.07	0.74	0.53	0.1	0.6	-0.23	0.64	0.55	0.78	0.64	-0.11	-0.72	-0.69		-0.21	0.78	-0.23	-0.33	0.78	0.52	0.82
Non Currrent Assets Other	-0.49	0.25	0.34	0.32	-0.53	0.66	-0.62	0.18	0.4	0.1	0.01	-0.51	-0.33	-0.45	-0.51	0.33	0.4	0.2	-0.21		-0.55	0.0	0.4	-0.19	-0.45	-0.56
Cash And Short Term Investments	0.98	0.19	-0.12	-0.33	0.99	-0.12	0.78	0.52	-0.06	0.3	-0.19	0.56	0.59	0.86	0.67	-0.11	-0.95	-0.57	0.78	-0.55		-0.19	-0.38	0.62	0.55	0.99
Common Stock Total Equity	-0.23	-0.29	-0.27	-0.29	-0.18	-0.27	-0.07	-0.32	0.02	0.19	1.0	-0.48	-0.06	-0.15	-0.49	-0.1	0.24	-0.17	-0.23	0.0	-0.19		-0.16	0.2	-0.44	-0.24
Non Current Liabilities Total	-0.43	-0.17	0.14	0.18	-0.37	0.39	-0.46	-0.25	0.55	-0.35	-0.16	-0.31	-0.31	-0.62	-0.28	-0.19	0.4	0.46	-0.33	0.4	-0.38	-0.16		-0.51	-0.24	-0.43
Other Stockholder Equity	0.7	0.43	-0.18	-0.49	0.63	-0.1	0.75	0.5	0.04	0.84	0.2	0.45	0.47	0.77	0.47	0.1	-0.58	-0.93	0.78	-0.19	0.62	0.2	-0.51		0.4	0.63
Property Plant And Equipment Gross	0.54	0.56	-0.15	-0.2	0.49	-0.3	0.79	0.35	-0.09	0.32	-0.44	0.87	0.43	0.68	0.98	-0.15	-0.48	-0.57	0.52	-0.45	0.55	-0.44	-0.24	0.4		0.54
Total Current Assets	0.99	0.21	-0.1	-0.26	0.99	-0.15	0.78	0.53	-0.12	0.29	-0.24	0.59	0.56	0.87	0.68	-0.13	-0.94	-0.55	0.82	-0.56	0.99	-0.24	-0.43	0.63	0.54

Click cells to compare fundamentals

Nephros Account Relationship Matchups

Nephros fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.6M	18.5M	17.7M	11.0M	11.9M	7.5M
Other Current Liab	300K	341K	444K	285K	794K	473.4K
Total Current Liabilities	2.4M	1.3M	2.4M	1.4M	2.1M	1.6M
Accounts Payable	959K	423K	1.3M	740K	873K	711.0K
Cash	4.2M	8.2M	7.0M	3.6M	4.3M	2.7M
Other Assets	32K	1.8M	89K	54K	62.1K	59.0K
Common Stock Shares Outstanding	7.5M	9.1M	10.0M	10.3M	10.4M	10.9M
Other Current Assets	61K	237K	225K	188K	132K	150.0K
Total Liab	3.9M	2.9M	2.9M	2.1M	3.5M	2.9M
Property Plant Equipment	1.2M	295K	1.1M	1.1M	1.3M	1.3M
Short Long Term Debt Total	2.5M	2.2M	1.1M	1.1M	1.8M	1.7M
Total Stockholder Equity	4.7M	12.5M	11.7M	5.6M	8.4M	8.8M
Property Plant And Equipment Net	1.2M	1.3M	1.1M	1.1M	2.0M	2.1M
Net Debt	(1.6M)	(6.1M)	(5.9M)	(2.5M)	(2.5M)	(2.3M)
Retained Earnings	(127.3M)	(131.9M)	(135.7M)	(142.8M)	(144.4M)	(151.6M)
Non Current Assets Total	3.3M	3.4M	4.0M	2.7M	3.5M	1.8M
Non Currrent Assets Other	18K	32K	89K	54K	86K	81.7K
Cash And Short Term Investments	4.2M	8.2M	7.0M	3.6M	4.3M	3.7M
Liabilities And Stockholders Equity	11.6M	18.5M	17.7M	11.0M	11.9M	7.8M
Non Current Liabilities Total	1.5M	1.6M	511K	706K	1.4M	2.0M
Other Stockholder Equity	131.9M	144.3M	147.3M	148.4M	152.8M	109.1M
Property Plant And Equipment Gross	1.2M	1.3M	1.1M	1.1M	2.9M	3.1M
Total Current Assets	8.3M	15.2M	13.6M	8.3M	8.4M	6.1M
Short Term Debt	1.0M	561K	612K	387K	446K	719.2K
Inventory	2.6M	5.3M	4.8M	3.2M	2.5M	1.4M
Net Receivables	1.0M	1.4M	1.6M	1.3M	1.5M	806.7K
Long Term Debt	623K	846K	95K	1K	900.0	855.0
Intangible Assets	1.4M	1.2M	2.1M	825K	652K	1.1M
Net Tangible Assets	2.6M	10.6M	8.9M	4.0M	4.6M	2.7M
Capital Surpluse	122.9M	127.8M	131.9M	144.3M	165.9M	134.3M

Currently Active Assets on Macroaxis

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America
C	Citigroup
V	Visa Class A

When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:

How To Invest In Nephros

Details

Is Nephros Stock a good investment?

Details

What is Nephros' Net Worth?

Details

Largest Medical Instruments & Supplies Companies

View

Largest Consumer Discretionary Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Nephros Stock analysis

When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.

	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Bonds Directory Find actively traded corporate debentures issued by US companies

Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.15)

Revenue Per Share

1.371

Quarterly Revenue Growth

0.272

Return On Assets

(0.09)

Return On Equity

(0.18)

The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nephros Cash And Short Term Investments vs Total Current Liabilities Analysis

Cash And Short Term Investments vs Total Current Liabilities

Cash And Short Term Investments vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Total Current Liabilities

Nephros fundamental ratios Correlations

Nephros Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nephros fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Nephros Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Common Stock
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash	+ 0.98	Total Assets

Cash And Short Term Investments	- 0.95	Net Debt
Total Current Assets	- 0.94	Net Debt
Net Debt	- 0.94	Cash
Other Stockholder Equity	- 0.93	Retained Earnings
Net Debt	- 0.92	Total Assets
Net Debt	- 0.82	Total Stockholder Equity